	US 11,931,407 B2
	MHC class I associated peptides for prevention and treatment of zika virus
Ramila Philip, Ivyland, PA (US)
Assigned to EMERGEX VACCINES HOLDING LIMITED, Abingdon (GB)
Filed by Emergex Vaccines Holding Limited, Oxfordshire (GB)
Filed on Aug. 29, 2022, as Appl. No. 17/898,069.
Application 17/898,069 is a division of application No. 16/644,123, granted, now 11,426,457, previously published as PCT/GB2018/052698, filed on Sep. 21, 2018.
Claims priority of provisional application 62/561,234, filed on Sep. 21, 2017.
Prior Publication US 2023/0129352 A1, Apr. 27, 2023
Int. Cl. A61K 39/12 (2006.01); A61K 9/51 (2006.01); A61K 39/00 (2006.01); A61P 31/12 (2006.01); C07K 14/18 (2006.01); C12N 15/113 (2010.01)

CPC A61K 39/12 (2013.01) [A61K 9/5115 (2013.01); A61K 39/001129 (2018.08); A61P 31/12 (2018.01); C07K 14/1825 (2013.01); C12N 15/1131 (2013.01); A61K 2039/57 (2013.01); A61K 2039/605 (2013.01)]

20 Claims

1. A vaccine composition comprising a flavivirus peptide comprising one or both of the CD8+ T cell epitopes set out in SEQ ID NOs: 9 and 10, or a variant thereof differing from the amino acid sequence of SEQ ID NO: 9 or 10 by insertion, deletion and/or substitution of up to three amino acids;

wherein the flavivirus peptide is between 8 and 20 amino acids in length.